Clinical studies are already underway investigating both GLP-1 analogues (Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI [POSTCON II]: ClinicalTrials.gov Identifier NCT00835848 and Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial: ClinicalTrials.gov Identifier NCT01254123) and DPP-4 inhibitors[39,40] as therapy for cardiovascular disease. This evidence concerns the gene DPP4 and myocardial infarction.